Sort   by:  
 Page size 
MetabolomicsStudy on the Hepatoprotection of Schisandra chinensis Caulis Ploysaccharides in nonalcoholic fatty liver disease in rats based on metabolomics

The aim of this study was to investigate the hepatoprotection of Schisandra chinensis Caulis polysaccharides (SCP) in the nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in rats. A total of 30 Wistar rats were randomly divided into control group (CON), model group...

2021-08-24 | MTBLS3194 | MetaboLights
MetabolomicsGut Microbiota Regulates Serum Metabolites in Mice with Nonalcoholic Fatty Liver Disease via Gut Metabolites: Mechanisms Involving Branched-Chain Amino Acids and Unsaturated Fatty Acids

In recent years, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease globally. Studies indicate that the gut-liver axis plays an important role in the occurrence and development of this disease. Our previous studies showed that the gut microbiota and gut meta...

2025-07-02 | MTBLS12668 | MetaboLights
MetabolomicsMulti-omic profiles of human nonalcoholic fatty liver disease tissue highlight heterogenic phenotypes
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms in, e.g. APOC3, ...
2015-12-07 | MTBLS174 | MetaboLights
MetabolomicsNonalcoholic fatty liver disease (NAFLD) Studies
Not available
ORGANISM(S): Homo sapiens 
ST000665 | MetabolomicsWorkbench
MetabolomicsGenome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by integrating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across the ...
2016-12-15 | MTBLS298 | MetaboLights
TranscriptomicsExpression data for Nonalcoholic fatty liver disease patients
Nonalcoholic fatty liver disease represents a spectrum of pathology that ranges from benign steatosis to potentially-progressive steatohepatitis and affects more than 30% of US adults. Advanced NAFLD is associated with increased morbidity and mortality from cirrhosis, primary liver cancer, cardiovas...
ORGANISM(S): Homo sapiens 
2013-08-30 | E-GEOD-49541 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human with nonalcoholic fatty liver disease against untreated controls
We analyzed the transcriptome for drug metabolism genes of 35 human (17 healthy control (HC), and 18 nonalcoholic fatty liver disease (NAFLD)) liver tissues, obtained during laparoscopic cholecystectomy. The aim of our study is to identify the drug metabolism genes significantly regulated by NAFLD a...
ORGANISM(S): Homo sapiens 
2022-12-19 | E-MTAB-12445 | biostudies-arrayexpress
TranscriptomicsExpression data from human non-alcoholic fatty liver disease stages
Global gene expression patterns of 2 human steatosis and 9 human non-alcoholic steatohepatitis (NASH) together with their respective control patterns were analyzed to define the non-alcoholic fatty liver disease (NAFLD) progression molecular characteristics and to define NASH early markers from stea...
ORGANISM(S): Homo sapiens 
2014-11-07 | E-GEOD-63067 | biostudies-arrayexpress
ProteomicsAmelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11
Nonalcoholic fatty liver disease (NAFLD) including its more severe manifestation, nonalcoholic steatohepatitis (NASH), is a global public health challenge. Here, we reveal a role for the deubiquitinating enzyme RPN11 in the development of NAFLD and NASH. Ablation of hepatic RPN11 markedly protected ...
ORGANISM(S): Homo Sapiens Mus Musculus 
2024-06-15 | PXD053163 |
Proteomics,MultiomicsPlasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis, where treatment options are limited. As the liver secrets most of the blood plasma proteins its diseases should affect the plasma proteome. Plasma proteome profiling on 48 patients with cirrhosis o...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000084333 | MassIVE
Sort   by:  
 Page size